Premium
Tumor prevention by a xanthate compound in experimental mouse‐skin tumorigenesis
Author(s) -
Fürstenberger G.,
Amtmann E.,
Marks F.,
Sauer G.
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430328
Subject(s) - tumor promotion , carcinogenesis , carcinogen , in vivo , cancer research , ratón , hyperplasia , anticarcinogen , pharmacology , skin tumor , tumor cells , chemistry , medicine , pathology , immunology , biology , biochemistry , cancer , microbiology and biotechnology
The antiviral and antitumoral compound tricyclodecan‐9‐yl‐xanthogenate (D609), which is an inhibitor of protein kinase C activation, has been used for tumor prevention in vivo. When applied chronically together with 12‐ O ‐tetradecanoylphorbol‐13‐acetate (TPA) in the classic initiationpromotion mouse‐skin model, D609 prevented tumor induction in a dose‐dependent manner. At the concentration that inhibited tumor formation by 97%, no toxic effects were detected and the TPA‐induced hyperplasia remained unaffected. As D609 failed to prevent the activity of a chronically applied carcinogen, it is concluded that the observed tumor prevention achieved with D609 is tumor‐promotion‐specific and is not due to killing of tumor cells.